Email this article CMV Reactivation in Myeloma Patients
Abstract
Reactivation of cytomegalovirus (CMV) has been considered a rare consequence of autologous stem cell transplants (ASCTs). However, the recent introduction of novel chemotherapy agents has been associated with an increased incidence of viral infections. We present a case of CMV reactivation in a patient with multiple myeloma who received novel chemotherapy agents for induction prior to ASCT. The authors make suggestions aimed at decreasing mortality in similar patients.
Clin Infect Immun. 2018;3(3-4):87-88
doi: https://doi.org/10.14740/cii68w
Clin Infect Immun. 2018;3(3-4):87-88
doi: https://doi.org/10.14740/cii68w
Keywords
Cytomegalovirus reactivation; Multiple myeloma; Autologous stem cell transplant